Clinical Trial Update: Canagliflozin Targeting Vascular Inflammation [Phase 2, Phase 3]

View source ↗

Summary

A trial update reports that canagliflozin is being studied for vascular inflammation in Phase 2 and Phase 3 trials, with recruiting ongoing for patients with ty…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Type 2 Diabetes Mellitus

Drugs mentioned

• Canagliflozin (canagliflozin)

Snippet

Sponsor: Ottawa Heart Institute Research Corporation | Conditions: Diabetes Type 2, Coronary Artery Disease | Phase 2, Phase 3 | Status: RECRUITING